CA2353531A1 - Materiaux hydrogels produisant du monoxyde d'azote - Google Patents
Materiaux hydrogels produisant du monoxyde d'azote Download PDFInfo
- Publication number
- CA2353531A1 CA2353531A1 CA002353531A CA2353531A CA2353531A1 CA 2353531 A1 CA2353531 A1 CA 2353531A1 CA 002353531 A CA002353531 A CA 002353531A CA 2353531 A CA2353531 A CA 2353531A CA 2353531 A1 CA2353531 A1 CA 2353531A1
- Authority
- CA
- Canada
- Prior art keywords
- macromer
- regions
- region
- tissue
- macromer composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Colloid Chemistry (AREA)
Abstract
L'invention concerne des hydrogels produisant du monoxyde d'azote (NO), de préférence photopolymérisables et biodégradables, pouvant libérer des quantités physiologiques de NO sur une durée prolongée, que l'on applique sur des sites ou à un patient nécessitant l'application de ce type de matériau pour le traitement de troubles comme la resténose, la thrombose, l'asthme, la cicatrisation, l'arthrite, la dysérection ou autres, dans lesquels le NO joue un rôle important. En règle générale, les hydrogels sont constitués de macromères, qui comprennent de préférence des zones biodégradables, et des groupes liés aux macromères sont libérés in situ, élevant ou modulant les niveaux de NO là où le traitement est requis. Les macromères peuvent former une homo ou hétéro-dispersion ou solution, polymérisée de manière à donner un matériau hydrogel qui, dans le dernier cas, peut être un réseau à semi-interpénétration ou à interpénétration. Les composés destinés à être libérés peuvent être physiquement emprisonnés, liés de façon covalente ou ionique au macromère, ou faire partie intégrante du matériau polymère. L'hydrogel peut être formé par réticulation ionique et/ou covalente. D'autres agents actifs (par exemple, thérapeutiques, prophylactiques ou diagnostiques) peuvent également être incorporés au matériau polymère.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15205499P | 1999-09-02 | 1999-09-02 | |
US60/152,054 | 1999-09-02 | ||
PCT/US2000/024058 WO2001015738A2 (fr) | 1999-09-02 | 2000-09-01 | Materiaux hydrogels produisant du monoxyde d'azote |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2353531A1 true CA2353531A1 (fr) | 2001-03-08 |
Family
ID=22541347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002353531A Abandoned CA2353531A1 (fr) | 1999-09-02 | 2000-09-01 | Materiaux hydrogels produisant du monoxyde d'azote |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1194171A2 (fr) |
AU (1) | AU7101600A (fr) |
CA (1) | CA2353531A1 (fr) |
CZ (1) | CZ20011899A3 (fr) |
IL (1) | IL143305A0 (fr) |
MX (1) | MXPA01005338A (fr) |
WO (1) | WO2001015738A2 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7279176B1 (en) | 1999-09-02 | 2007-10-09 | Rice University | Nitric oxide-producing hydrogel materials |
US7052711B2 (en) | 1999-09-02 | 2006-05-30 | Rice University | Nitric oxide-producing hydrogel materials |
AU2001263281A1 (en) * | 2000-05-18 | 2001-11-26 | Genetix Pharmaceuticals, Inc. | Polyethylene glycol (peg) polymers for the promotion of angiogenesis |
JP4841066B2 (ja) * | 2000-09-01 | 2011-12-21 | ライスユニバーシティ | 酸化窒素生成ヒドロゲル物質 |
CA2459891C (fr) | 2001-09-05 | 2014-02-04 | Cyterra Corporation | Methode et appareil de production d'oxyde nitrique |
CA2488230C (fr) | 2002-04-29 | 2013-04-09 | Yves Claude Nicolau | Inositol pyrophosphates et procede d'utilisation desdits composes |
CA2487720A1 (fr) * | 2002-06-03 | 2003-12-11 | Alnis Biosciences, Inc. | Agent therapeutique contenant des nanoarticles polymeriques |
EP1789119B1 (fr) | 2004-08-18 | 2017-10-18 | Geno LLC | Conversion de dioxyde d'azote (no2) en monoxyde d'azote (no) |
US7618594B2 (en) | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
CA2912259C (fr) | 2005-05-27 | 2020-04-28 | Mark H. Schoenfisch | Particules liberant de l'oxyde nitrique pour therapie a base d'oxyde nitrique et applications biomedicales |
US7947227B2 (en) | 2007-03-23 | 2011-05-24 | Geno Llc | Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
CA2713049C (fr) | 2008-01-28 | 2017-02-28 | Geno Llc | Conversion de dioxyde d'azote (no<sb>2</sb>) en monoxyde d'azote (no) |
US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
AU2010263098B2 (en) | 2009-06-22 | 2016-01-07 | VERO Biotech LLC. | Nitric oxide therapies |
WO2011022652A1 (fr) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Gels topiques |
BR112012003804B1 (pt) | 2009-08-21 | 2019-02-19 | Novan, Inc. | Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento |
AU2010321707B2 (en) | 2009-11-20 | 2016-03-17 | VERO Biotech LLC. | Nitric oxide delivery system |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012118819A2 (fr) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Particules de silice modifiées par des groupements s-nitrosothiols libérant de l'oxyde nitrique et procédés de fabrication associés |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5910316A (en) * | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
US5691423A (en) * | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
US5797887A (en) * | 1996-08-27 | 1998-08-25 | Novovasc Llc | Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation |
HUP9801673A1 (hu) * | 1998-07-24 | 2000-08-28 | CYCLOLAB, Ciklodextrin Kutató-Fejlesztő Kft. | Helyi vérbőséget fokozó gyógyszerkészítmények előállítása és alkalmazása |
-
2000
- 2000-09-01 CA CA002353531A patent/CA2353531A1/fr not_active Abandoned
- 2000-09-01 WO PCT/US2000/024058 patent/WO2001015738A2/fr not_active Application Discontinuation
- 2000-09-01 EP EP00959750A patent/EP1194171A2/fr not_active Withdrawn
- 2000-09-01 IL IL14330500A patent/IL143305A0/xx unknown
- 2000-09-01 AU AU71016/00A patent/AU7101600A/en not_active Abandoned
- 2000-09-01 CZ CZ20011899A patent/CZ20011899A3/cs unknown
- 2000-09-01 MX MXPA01005338A patent/MXPA01005338A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA01005338A (es) | 2003-07-14 |
WO2001015738A2 (fr) | 2001-03-08 |
AU7101600A (en) | 2001-03-26 |
IL143305A0 (en) | 2002-04-21 |
CZ20011899A3 (cs) | 2001-11-14 |
WO2001015738A3 (fr) | 2002-01-31 |
EP1194171A2 (fr) | 2002-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7279176B1 (en) | Nitric oxide-producing hydrogel materials | |
US7052711B2 (en) | Nitric oxide-producing hydrogel materials | |
JP4841066B2 (ja) | 酸化窒素生成ヒドロゲル物質 | |
KR100266912B1 (ko) | 조직접촉물질이며 방출조절운반체인 광중합성 생분해성 하이드로겔 | |
CA2353531A1 (fr) | Materiaux hydrogels produisant du monoxyde d'azote | |
US5626863A (en) | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers | |
US5410016A (en) | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers | |
Sawhney et al. | Bioerodible hydrogels based on photopolymerized poly (ethylene glycol)-co-poly (. alpha.-hydroxy acid) diacrylate macromers | |
Bohl et al. | Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation | |
US7022343B2 (en) | Controlled release of anti-arrhythmic agents | |
CA2121129A1 (fr) | Polysaccharides pouvant etre reticules, polycations et lipides, utiles pour l'encapsulation et la liberation controlee de medicaments | |
US20020192182A1 (en) | Polysaccharide-based polymerizable hydrogels | |
US20040138329A1 (en) | Gels for encapsulation of biological materials | |
AU711031B2 (en) | Covalent modification of surfaces with polymers to increase biocompatibility | |
WO1997032617A9 (fr) | Modification covalente de surfaces au moyen de polymeres pour un accroissement de la biocompatibilite | |
EP1586349A1 (fr) | Libération contr lée d'agents anti-arrhythmiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |